Head to head
Starling Oncology vs HCA Healthcare
Side-by-side on the measures that matter, with a plain-English read. Full detail: STLN · HCA
STLN
Starling Oncology
6.43-2.28%
1-year price shape — +68% over the period
Quant Rating B · 82/100
vs
HCA
HCA Healthcare
439.17+1.61%
1-year price shape — +1% over the period
Quant Rating D · 41/100
1-year performance, rebased to 100
HCA Healthcare edges it on the scoreable measures. HCA Healthcare pays the highest dividend yield; HCA Healthcare earns the most per share.
| STLN | HCA | |
|---|---|---|
| Snapshot | ||
| Sector | Medical Care Facilities | -- |
| Last price | 6.43 | 439.17 |
| Change today | -2.28% | +1.61% |
| 1-year return | +68.3% | +0.9% |
| Market cap | $655.32M | $95.08B |
| 52-week range | 2.32 – 7.13 | 353.34 – 553.56 |
| Valuation | ||
| P/E (TTM) | -22.17 | 14.73 |
| P/E percentile, own 5-yr range | 27th | 55th |
| P/B | -26.35 | -14.32 |
| Dividend yield | 0.00% | 0.68% |
| Profitability & growth | ||
| EPS (TTM) | -0.54 | 28.33 |
| Net profit (TTM) | $-55.03M | $6.13B |
| Revenue (TTM) | $587.24M | $78.01B |
| Revenue growth (YoY) | +34.6% | +8.7% |
| Gross margin | 15.7% | 42.6% |
| Operating margin | -4.4% | 15.5% |
| Net margin | -5.2% | 8.8% |
| Free cash flow (TTM) | $-3.29M | $6.00B |
| Ownership & sentiment | ||
| Institutional ownership | 48.1% | 94.6% |
| Insider activity (12mo) | 32 buy / 18 sell | 22 buy / 23 sell |
| Short interest (% of float) | 6.9% | 3.0% |
| Analyst consensus | 100% buy (3) | 64% buy / 32% hold / 5% sell (22) |
| Analyst price target | $9 (+40%) | $457 (+4%) |
| StockVane view | ||
| StockVane Quant Rating | B (82) | D (41) |
| Company | ||
| Employees | 641 | 320,000 |
| Founded | 2007 | 1968 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.